On Friday, Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) opened lower -0.92% from the last session, before settling in for the closing price of $7.60. Price fluctuations for BCRX have ranged from $4.03 to $8.88 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 190.00% annually for the last half of the decade. Company’s average yearly earnings per share was noted 68.26% at the time writing. With a float of $189.02 million, this company’s outstanding shares have now reached $207.12 million.
In an organization with 536 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.91%, operating margin of -9.84%, and the pretax margin is -30.09%.
Biocryst Pharmaceuticals Inc (BCRX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Biocryst Pharmaceuticals Inc is 8.74%, while institutional ownership is 78.73%. The most recent insider transaction that took place on Dec 13 ’24, was worth 52,584. Before that another transaction happened on Jun 24 ’24, when Company’s Director sold 8,600 for $6.32, making the entire transaction worth $54,352. This insider now owns 27,831 shares in total.
Biocryst Pharmaceuticals Inc (BCRX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 68.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 44.80% during the next five years compared to -3.73% drop over the previous five years of trading.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Trading Performance Indicators
Check out the current performance indicators for Biocryst Pharmaceuticals Inc (BCRX). In the past quarter, the stock posted a quick ratio of 2.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.61, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.09 in one year’s time.
Technical Analysis of Biocryst Pharmaceuticals Inc (BCRX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.54 million. That was inferior than the volume of 2.85 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 52.70%. Additionally, its Average True Range was 0.35.
During the past 100 days, Biocryst Pharmaceuticals Inc’s (BCRX) raw stochastic average was set at 43.51%, which indicates a significant increase from 40.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.03% in the past 14 days, which was lower than the 50.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.61, while its 200-day Moving Average is $6.71. However, in the short run, Biocryst Pharmaceuticals Inc’s stock first resistance to watch stands at $7.63. Second resistance stands at $7.73. The third major resistance level sits at $7.82. If the price goes on to break the first support level at $7.43, it is likely to go to the next support level at $7.34. Assuming the price breaks the second support level, the third support level stands at $7.24.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Key Stats
There are currently 207,133K shares outstanding in the company with a market cap of 1.55 billion. Presently, the company’s annual sales total 331,410 K according to its annual income of -226,540 K. Last quarter, the company’s sales amounted to 117,090 K and its income totaled -14,030 K.
